Tradestie Institutional Equity Comparison Engine
FEMY vs RNAZ โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RNAZ Overall Edge
RNAZ Captures Institutional Edge (1โ1 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to TransCode Therapeutics, Inc. Common Stock (RNAZ) driven by superior Growth & Margin while FEMY counters with relative strength in Momentum & Technical. Fundamentally, FEMY trades at N/M Forward P/E with -763.9% operating margin (-18.9% YoY revenue) versus RNAZ at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FEMY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against RNAZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
FEMY N/M vs RNAZ N/M Fwd P/E
Growth & Margin Winner
RNAZ
Op Margin -763.9% vs 0.0% ยท YoY -18.9% vs +0.0%
Momentum & Technical Winner
FEMY
1Y +54.8% vs -85.6% ยท 52W Pos 17% vs 0%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
FEMY
NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap
$11.9M
1M Return
-22.42%
1Y Return
+54.78%
Forward P/E
N/M
Unified AI Score
52.6 / 100
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
RNAZ
NASDAQ
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.35
+2.27% 1D
Market Cap
$22.3M
1M Return
-20.59%
1Y Return
-85.64%
Forward P/E
N/M
Unified AI Score
50.3 / 100
HOLD
Tech 53.0
Fund 48.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FEMY +54.78%
RNAZ -85.64%
Spread: +138.75 pp (FEMY Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FEMY TTM Op. Margin: -763.9%
RNAZ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FEMY vs RNAZ. Trailing 12-month operating profitability (FEMY -763.9% vs RNAZ 0.0%) and valuation multiples (FEMY N/M vs RNAZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FEMY | RNAZ | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $11.9M | $22.3M | Larger Scale | RNAZ |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -18.9% | +0.0% | Higher Growth | RNAZ |
| Operating Margin (TTM) Profitability | -763.9% | 0.0% | Higher Margin | RNAZ |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -425.0% | -59.3% | Higher ROE | RNAZ |
| 52-Week Range Position Momentum | 17% ($0โ$6) | 0% ($1โ$13) | Stronger Trend | FEMY |
| Beta / 30D Volatility Risk Regime | 4.01ฮฒ ยท 72% Vol | 0.96ฮฒ ยท 63% Vol | Lower Realized Risk | RNAZ |
| Unified Institutional Score Composite Signal | 52.6 / 100 (HOLD) | 50.3 / 100 (HOLD) | Higher Composite | FEMY |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FEMY vs RNAZ Buy Guide
FEMY
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
RNAZ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FEMY nor RNAZ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.